LOS ANGELES, Feb. 13, 2024 /PRNewswire/ -- TETROUS, INC. unveils the addition of EnFix TAC to its family of EnFix™ demineralized bone allograft implants for use in rotator cuff surgery. The new implants will be showcased this week at the American Academy of Orthopaedic Surgeons (AAOS) annual conference in San Francisco, CA..

洛杉矶，2024年2月13日/PRNewswire/--TETROUS，INC.宣布将EnFix TAC添加到其EnFix™脱矿质同种异体骨植入物家族中，用于肩袖手术。新植入物将于本周在加利福尼亚州旧金山举行的美国骨科医师学会（AAOS）年会上展出。。

Our technology is focused on healing the bone-to-tendon interface known as the enthesis.

我们的技术专注于愈合被称为肌腱的骨-肌腱界面。

A regenerative medicine company guided by a team of influential surgeons, regenerative medicine scientists, and business leaders with experience in the orthopaedic space, Tetrous is focused on the unmet need in bone-to-tendon healing following orthopaedic surgery. Numerous clinical and preclinical studies show that the enthesis does not re-form following surgery, but instead results in the formation of scar tissue.

Tetrous是一家再生医学公司，由一群有影响力的外科医生，再生医学科学家和在整形外科领域有经验的商业领袖领导，专注于整形外科手术后骨到肌腱愈合的未满足需求。许多临床和临床前研究表明，手术后不会重新形成，而是导致瘢痕组织的形成。

Scar tissue does not allow proper transmission of tensile load from soft tissue to bone and is prone to fail..

疤痕组织不允许拉伸载荷从软组织正确传递到骨骼，并且容易失败。。

'With strong pre-clinical data and promising early clinical results showing healing at the bone-to-tendon interface following surgery using our EnFix RC demineralized bone fiber implant, we are excited to add EnFix TAC to our product line,' stated John Bojanowski, Tetrous' Chief Commercialization Officer.

Tetrous首席商业化官约翰·博亚诺夫斯基（JohnBojanowski）表示：“凭借强大的临床前数据和令人鼓舞的早期临床结果，我们使用EnFix RC脱矿质骨纤维植入物进行手术后，骨-肌腱界面愈合，我们很高兴将EnFix TAC添加到我们的产品线中。”。

'EnFix TAC is specifically designed to deliver the same enthesis healing properties while offering the flexibility to be used independently of the surgeon's suture anchor choice, readily accommodating surgeons who are moving to all-suture anchors.'.

“EnFix TAC专门设计用于提供相同的附着点愈合特性，同时提供独立于外科医生的缝合锚选择而使用的灵活性，易于容纳正在移动到所有缝合锚的外科医生。”。

'The EnFix TAC comes in two shapes to provide optimal coverage of the bony real estate available based on the size of the rotator cuff tear,' stated Andy Carter, Ph.D., Co-Founder and CTO. 'Our technology is focused on healing the bone-to-tendon interface known as the enthesis. Clinical literature shows healing does not occur on its own.

联合创始人兼首席技术官安迪·卡特（AndyCarter）博士说：“EnFix TAC有两种形状，可以根据肩袖撕裂的大小提供最佳的骨骼覆盖范围。”我们的技术专注于愈合骨与肌腱的界面，称为肌腱。临床文献显示愈合不会自行发生。

Whilst our initial products focus on the rotator cuff, we are also working on additional applications for ACL and achilles repair as product line extensions in the EnFix family. We were pleased to have two US patents granted in 2023 covering the EnFix devices and we continue to grow our patent portfolio.'.

虽然我们最初的产品专注于肩袖，但我们也在致力于ACL和跟腱修复的其他应用，作为EnFix系列的产品线扩展。我们很高兴在2023年获得了两项涉及EnFix设备的美国专利，并且我们继续扩大我们的专利组合。”。

Tetrous products are currently being distributed in the United States and Australia, manufactured by established local tissue banks that have extensive experience with the technology.

Tetrous产品目前正在美国和澳大利亚销售，由拥有丰富技术经验的当地纸巾库制造。

About Tetrous, Inc.

关于Tetrous，Inc。

Founded in 2019, Tetrous, Inc. utilizes next generation advanced technologies for enthesis repair in sports medicine applications. The first offerings in the EnFix family of products are EnFix RC and EnFix TAC for rotator cuff repair. Tetrous was conceived from technology developed for spine surgery.

Tetrous，Inc.成立于2019年，利用下一代先进技术在运动医学应用中进行修复。EnFix系列产品中的首批产品是用于肩袖修复的EnFix RC和EnFix TAC。Tetrous是从脊柱手术开发的技术中构思出来的。

The Company is employing and expanding the technology for novel applications in sports medicine. Its core technology has been used in nearly 150,000 surgeries in spine applications. The demineralized bone fiber technology used in Tetrous products is licensed exclusively for use in sports medicine from TheraCell, an ISTO Biologics Company.

该公司正在采用和扩大该技术在运动医学中的新应用。其核心技术已用于近150000例脊柱手术。Tetrous产品中使用的脱矿质骨纤维技术由ISTO生物制品公司TheraCell独家授权用于运动医学。

EnFix™, EnFix RC™ and EnFix TAC™ are trademarks of Tetrous, Inc..

EnFix™、EnFix RC™和EnFix TAC™是Tetrous，Inc.的商标。。

For more information visit www.tetrous.com and follow us on LinkedIn (www.linkedin.com/company/tetrous).

有关更多信息，请访问www.tetrous.com，并在LinkedIn（www.LinkedIn.com/company/tetrous）上关注我们。

Media Contact:

媒体联系人：

Product Information:

产品信息：

Bradley Patt, PhD

Bradley Patt博士

Tetrous, Inc.

Tetrous公司。

331-307-7499

331-307-7499

bpatt@tetrous.com

bpatt@tetrous.com

John Bojanowski

John Bojanowski

Tetrous, Inc.

Tetrous公司。

331-307-7499

331-307-7499

jbojanowski@tetrous.com

jbojanowski@tetrous.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/tetrous-inc-announces-the-launch-of-the-enfix-tac-to-complement-the-enfix-rc-as-the-only-product-line-of-100-demineralized-bone-allograft-implants-that-are-designed-to-enhance-reformation-of-the-enthesis-in-rotator-cuff-surge-302059943.html.

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/tetrous-inc-announces-the-launch-of-the-enfix-tac-to-complement-the-enfix-rc-as-the-only-product-line-of-100-demineralized-bone-allograft-implants-that-are-designed-to-enhance-reformation-of-the-enthesis-in-rotator-cuff-surge-302059943.html.

SOURCE Tetrous

源Tetrous